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https://doi.org/10.1016/j.stemcr.2017.10.019SUMMARYHepatocyte-like cells (HLCs) can be generated through directed differentiation or transdifferentiation. Employing two strategies, we
generated induced pluripotent stem cell (iPSC)-HLCs and hiHeps from the same donor cell line. Both types of HLCs clustered distinctly
from each other during gene expression profiling. In particular, differences existed in gene expression for phase II drug metabolism and
lipid accumulation, underpinned by H3K27 acetylation status in iPSC-HLCs and hiHeps. While distinct phenotypes were achieved
in vitro, both types of HLCs demonstrated similar phenotypes following transplantation into Fah-deficient mice. In conclusion, func-
tional HLCs can be obtained from the same donor using two strategies. Global gene expression defined the differences between those
populations in vitro. Importantly, bothHLCs displayed partial butmarkedly improved hepatic function following transplantation in vivo,
demonstrating plasticity and the potential for cell-based modeling in the dish and cell-based therapy in the future.INTRODUCTION
In order to overcome the limitations of using human hepa-
tocytes from donor liver organs, methods to derive hepato-
cyte-like cells (HLCs) from other cells have been studied
intensively (Forbes et al., 2015; Rezvani et al., 2016). To
date, many different types of HLCs have been successfully
generated from human pluripotent stem cells (hPSCs),
with some derivative HLCs exhibiting respectable human
drug metabolism and liver repopulation in vivo (Rezvani
et al., 2016). hPSC-HLCs are typically obtained from hPSCs
in a stage-wise process (Gerbal-Chaloin et al., 2014; Hay
et al., 2008; Si-Tayeb et al., 2010; Sullivan et al., 2010; Tou-
boul et al., 2010), whereas hiHeps are obtained by directing
cellular transdifferentiation from human fibroblasts, or
other cell types, by the forced expression of specific hepato-
cyte transcription factors (Du et al., 2014; Huang et al.,
2014). To understand the advantages of both systems, a sys-
temic comparison between induced pluripotent stem cell
(iPSC)-HLCs and hiHeps is necessary to realize their trans-
lational value and understand the basic mechanisms that
underpin hepatic differentiation and liver organogenesis
(Forbes et al., 2015). While studies have been performed
in PSCs, derived from the inner cellmass of nuclear transferStem Cell Reports
This is an open access article under the Cembryos, and iPSCs (Ma et al., 2014), a systematic study
comparing iPSC-HLCs and hiHeps from the same donor
has not been performed.
PSC-HLCs generated by different protocols were
compared in a recent study (Godoy et al., 2015). On the ba-
sis of gene expression, gene networks were established to
predict for successful or failed hepatocyte differentiation.
In these studies, HNF1, FXR, and PXR were highlighted as
key transcription factors required to improve HLC differen-
tiation. In a similar approach, we have performed direct
comparison of iPSC-HLC and hiHep gene expression and
function in vitro and in vivo. This is of the utmost impor-
tance as iPSC-HLCs and hiHeps demonstrate significant
potential in the quest to accurately model human disease
and develop immune-matched cell-based therapies for the
clinic (Bhatia et al., 2014; Fox et al., 2014).More specifically,
our studies provide important information on the mecha-
nisms that underlie cell identity changes during the process
of liver differentiation and regeneration (Szkolnicka and
Hay, 2016). Umbilical cord-derived fibroblasts (UCFs)
were used in these studies. They were isolated from the
same donor prior to reprogramming and directed differen-
tiation or transdifferentiation, thereby removing the influ-
ence of genetic variation observed in the populationj Vol. 9 j 1813–1824 j December 12, 2017 j ª 2017 The Author(s). 1813
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(Kajiwara et al., 2012). In summary, our studies focused on
global gene expression and epigenetic remodeling to better
understand the circuitry that underpins successful hepatic
specification and cell function in vitro and in vivo.RESULTS
Generation of Functional iPSC-HLCs and hiHeps from
the Same Donor
Human umbilical cord fibroblasts, UCF1 and UCF2, were
generated from two individuals (Figures S1A and S1B).
The UCF donor cells were reprogrammed to iPSCs using
standard methodology (Takahashi et al., 2007). The deriva-
tive iPSC lines were termed iPSC1 (derived fromUCF1) and
iPSC2 (derived from UCF2). Both lines expressed pluripo-
tent stem cell markers (NANOG and SSEA4) and were
positive for alkaline phosphatase (Figures S2A–S2D). In
association with increased OCT4 expression, the promoter
of OCT4 was demethylated (Figure S2E). After transplanta-
tion into the immune-deficient mice, both iPSC lines
formed teratomas comprising tissues derived from the
three germ layers (Figure S2F). Taken together, these results
confirm that we produced two bona fide iPSC lines that
could be maintained with normal karyotype for more
than 40 passages (Figure S2G).
Both iPSC cells were differentiated into HLCs following a
published protocol (Szkolnicka et al., 2014). We also trans-
differentiated UCF1 and UCF2 into hiHep using FOXA3,
HNF1A, and HNF4A as previously published (Huang
et al., 2014) (Figure 1A). To confirm cell identity, hiHeps
and iPSC-HLCs were validated to be genetically identical
with the parental lines by short tandem repeat typing
(Table S1). Morphologically, both hiHeps and iPSC-HLCs
displayed typical epithelial phenotype, forming tight junc-
tions, and canaliculi monolayers became confluent (Fig-
ure 1B). Interestingly, the diameter of the iPSC-HLCs was
approximately 25% larger than that of hiHeps (12.6 mm
in hiHeps versus 15.8 mm in iPSC-HLCs). A more detailed
analysis demonstrated that the expression levels of typical
hepatic markers were comparable between hiHeps and
iPSC-HLCs, and those approached the levels detected in
primary human hepatocytes (PHHs) as determined by
qPCR (Figure 1C). Hepatocellular specification was also
monitored by flow cytometry, and around 80% hiHeps
and iPSC-HLCs co-expressed ALBUMIN and a-1-antitryp-
sin (AAT) (Figure 1D). The expression and secretion of
ALBUMIN and AATwere further confirmed by ELISA, using
supernatants from iPSC-HLCs and hiHeps. Of note, both
proteins were detected at levels comparable with that in
PHH cultures (Figure S3A). These data together indicate
that iPSC-HLC and hiHep cells were homogeneous popula-
tions displaying typical hepatocyte features.1814 Stem Cell Reports j Vol. 9 j 1813–1824 j December 12, 2017Differential Hepatocyte Gene Expressions in iPSC-
HLCs and hiHeps
Following our initial characterization, we preformed
genome-wide profiling of iPSC-HLCs and hiHeps and
compared their gene expression (Table S2) with UCFs and
PHHs controls. The top 4,000 most variably expressed
genes between UCFs and PHHs that cultured for 1, 2, and
4 days were selected for further analysis. Whole-genome
analysis using principal component analysis (PCA)
confirmed that iPSC-HLCs, hiHeps, UCFs, and PHHs were
clustered into distinct groups (Figure 2A).
Following this, we focused our analyses on differential
gene expression between iPSC-HLCs and hiHeps. Unsuper-
vised clustering of hepatic genes was performed, following
with gene ontology enrichment analysis (Figures 2B and
2C). Based on the different gene expression patterns of
hiHeps, iPSC-HLCs, and PHHs, the highly expressed hepat-
ic genes could be divided into seven clusters. Genes
involving fat digestion and absorption (e.g., FABP1,
APOB) and metabolism enzymes (e.g., GPX3 and ACOX1)
were enriched in cluster I; their expression was induced
in both hiHeps and iPSC-HLCs. There were some hepatic
genes showing low expression in both iPSC-HLCs and
hiHeps (cluster IV), including cytochrome P450-based
metabolism genes (e.g., CYP2C9, CYP2E1, and CYP3A4)
and coagulation complements (e.g., F5, F9, and F11).
Genes in cluster II were highly expressed in hiHeps but
not in iPSC-HLCs. For example, the phase II metabolic en-
zymes (e.g., UGT1A1 and UGT1A6) and ABC transporters
(e.g., ABCC2 and ABCB1) were highly enriched in cluster
II genes. The expression of genes in cluster III was induced
in iPSC-HLCs, and included fat digestion and absorption
genes (e.g., APOA2 and FASN) and bile secretion genes
(e.g., OATPB and NTCP) (Figure 2C). Moreover, in clusters
V, VI, and VII, the typical fibrotic genes and pathways
were downregulated in HLCs (Figure S4A). Taken together,
these studies highlighted differential gene expression
between iPSC-HLCs and hiHeps.
Comparison of hiHep and iPSC-HLC Function In Vitro
Whole-genome analyses of expression profiles elucidated
differences between iPSC-HLCs and hiHeps. To understand
its functional implications, wemeasured several key hepat-
ic functions in both cell types. As highlighted from gene
expression analyses, both cells carried comparable levels
of glycogen storage abilities as determined by periodic
acid-Schiff (PAS) staining and colorimetric assay (Figures
3A and 3B).
To investigate phase I cytochrome P450 (CYP) induction,
we treated hiHeps and iPSC-HLCs with 3-methylcholan-
threne, phenobarbital, and rifampicin. hiHeps and iPSC-
HLCs also possessed remarkable capacities to respond to
these chemicals (Figures S3B and S3C). We specifically
Figure 1. Generation of Hepatocyte-like
Cells (HLCs) by Different Strategies
(A) Schematic diagram of the generation of
HLCs by different strategies.
(B) Typical morphology of UCF, hiHep, and
iPSC-HLC. hiHep1 and iPSC-HLC1 were
derived from UCF1. Scale bar, 100 mm.
(C) Hepatic gene expression levels of HLCs
were measured by qPCR. UCF included two
independent replicates, UCF1 and UCF2;
hiHep included four replicates from inde-
pendent experiments (hiHep1, hiHep2,
hiHep3, and hiHep4); iPSC-HLC included
four replicates from independent experi-
ments (iPSC-HLC1, iPSC-HLC2, iPSC-HLC3,
and iPSC-HLC4); PHH included two inde-
pendent replicates that were cultured for
2 days.
(D) Both hiHeps and iPSC-HLCs displayed a
high percentage of ALB and AAT double-
positive cells, as measured by flow cy-
tometry. UCFs were used as negative control
and PHHs cultured for 2 days were used as
positive control.
See also Figures S1 and S2 and Table S1.measured testosterone elimination as an indication of
CYP3A function in iPSC-HLCs and hiHeps. Both cells could
eliminate testosterone to 20%–30% of the original level
within 4 hr (Figure 3C). This was approximately 10- to 15-fold less than PHHs.We next analyzed the biliary excretion
capabilities. Both hiHeps and iPSC-HLCs expressed biliary
excretion-related transporters (Figure S3D) and showed a
high biliary excretion index (BEI), effluxing substratesStem Cell Reports j Vol. 9 j 1813–1824 j December 12, 2017 1815
Figure 2. Transcriptome Analysis of
hiHeps and iPSC-HLCs
(A) Principal component analysis (PCA) of
four cell types using 4,000 genes with
highest variance in UCFs and PHHs cultured
for 1, 2, and 4 days. The percentages on the
axes represent the variance explained by
the respective axes. hiHep1 and hiHep2
were derived from UCF1, hiHep3 and hiHep4
were derived from UCF2; iPSC-HLC1 and
iPSC-HLC2 were derived from iPSC1, iPSC-
HLC3 and iPSC-HLC4 were derived from
iPSC2. PHHs were fresh, or cultured for 1, 2,
and 4 days.
(B) Hierarchical clustering of UCFs, hiHeps,
iPSC-HLCs, and PHHs using 4,000 genes
with highest variance in UCFs and PHHs
cultured for 1, 2, and 4 days. The samples
are the same as (A).
(C) Enriched pathways and representative
genes in different cluster groups are sum-
marized.
See also Figure S4 and Table S2.cholyl-lysyl-fluorescein (CLF), D8-taurocholic acid (D8-
TCA), and rosuvastatin at similar levels to PHH (Figure S3E).
These results suggested that hiHeps and iPSC-HLCs
possessed multiple hepatic functions at comparable levels.
Despite the above similarity between iPSC-HLCs and
hiHeps, expression profile analysis predicted that iPSC-
HLCs had faster lipid metabolism than hiHeps, whereas
hiHeps might perform better in phase II metabolism.
Indeed, lipid formation and accumulation in iPSC-HLCs
was similar to that in PHHs and almost double than that
in hiHeps (Figures 3D and 3E). In accordance with the tran-
scriptomic datasets, we observed that hiHeps possessed
greater UGT activity than iPSC-HLCs (Figure 3F).
Understanding iPSC-HLCs and hiHeps Cell Identity
In Vitro
Next, we asked whether iPSC-HLCs and hiHeps retain mo-
lecular traces of their induction processes and whether1816 Stem Cell Reports j Vol. 9 j 1813–1824 j December 12, 2017thosemolecular traces are important components of hiHep
and iPSC-HLC cell identity. We first characterized the elim-
ination of fibroblast-specific gene expression in iPSC-HLCs
and hiHeps. Markedly, fibroblast-related genes, selected
according to published data (Buganim et al., 2012; Huang
et al., 2014), were significantly extinguished in both
iPSC-HLCs and hiHeps. Those included COL1A1,
COL1A2, MMP14, and LOXL2 (Figures 4A, S4B, and S4C).
However, some fibrotic genes were expressed at low levels
in both iPSC-HLCs and hiHep cells (Figure 4A). These
data suggest that the original fibroblast identity was
efficiently but not fully erased in both hiHeps and iPSC-
HLCs.
We next investigated whether iPSC-HLCs and hiHeps
retain any molecular traces related to transdifferentiation
and differentiation. We first analyzed marker genes of
bile duct cells, which share common progenitors with
hepatocytes. Expression pattern analysis did not show
Figure 3. Functional Characterizations of
hiHeps and iPSC-HLCs
(A) Glycogen storage in different HLCs was
measured by periodic acid-Schiff (PAS)
staining. Scale bar, 100 mm.
(B) Glycogen storage in HLCs was deter-
mined quantitatively by colorimetric mea-
surement (Abnova). UCF included two
independent replicates, UCF1 and UCF2;
hiHep included four replicates from inde-
pendent experiments (hiHep1, hiHep2,
hiHep3, and hiHep4); iPSC-HLC included
four replicates from independent experi-
ments (iPSC-HLC1, iPSC-HLC2, iPSC-HLC3,
and iPSC-HLC4). PHH included two repli-
cates cultured for 2 days from independent
experiments.
(C) HLCs both eliminated testosterone as
efficiently as PHHs. Concentrations of
testosterone were determined by liquid
chromatography-tandem mass spectrom-
etry. Each time point had three replicates
from independent experiments.
(D) iPSC-HLCs showed more lipid accumu-
lation than hiHep as measured by oil red O
staining. Scale bar, 100 mm.
(E) Lipid accumulation was quantified by oil
lipid numbers per cell. UCF had two inde-
pendent replicates, UCF1 and UCF2; hiHep
had four replicates from independent ex-
periments (hiHep1, hiHep2, hiHep3, and
hiHep4); iPSC-HLC had four replicates from
independent experiments (iPSC-HLC1, iPSC-
HLC2, iPSC-HLC3, and iPSC-HLC4). PHH
included two replicates cultured for 2 days
from independent experiments. There was a
significant difference between hiHep and
iPSC-HLC. *p < 0.05.
(F) UGT activities of hiHeps and iPSC-HLCs were determined by the luminescence of remaining substrates. The combination of replicates is
the same as in (E). There was a significant difference between hiHep and iPSC-HLC. *p < 0.05.
See also Figure S3.significant bile duct gene expression in both hiHeps and
iPSC-HLCs (Figure 4B). Following this, we analyzed for
the expression of colon-specific genes (Forster et al.,
2014). Notably, the expression of colon-specific genes was
undetectable in hiHeps, indicating the specificity of the
applied hepatic transdifferentiation protocol (Figure 4C).
Interestingly, CDX2 was detected at low levels in iPSC-
HLCs, indicating that low-level colon signatures persist
in vitro (Figure S5C).
Following these studies, we characterized whether iPSC-
HLCs retain molecular traces of endoderm progenitors
(Cheng et al., 2012; Loh et al., 2014) and hepatoblasts
(Yu et al., 2013). Intriguingly, iPSC-HLCs expressed several
marker genes for endoderm progenitors (including FOXA2and GATA6), and hepatoblasts (including AFP and EPCAM)
(Figures 4D, 4E, and S4D). In contrast, these progenitor
marker genes were undetectable in hiHeps, while the
iPSC-HLCs expressed less ALBUMIN and TAT mRNA than
the hiHep as shown in RNA-seq analysis (Figure S4D).
The expression of progenitor marker genes was validated
by q-PCR in iPSC-HLCs (Figure S5A). We performed co-
staining for ALB (a marker for mature hepatocytes) and
AFP (a marker for immature hepatocytes) in HLCs (Fig-
ure S5B). It was striking that almost all iPSC-HLCs were
double positive for ALB and AFP, whereas no AFP-positive
cells were detectable in hiHeps, suggesting that iPSC-
HLCs retained some progenitor traces during the differen-
tiation process.Stem Cell Reports j Vol. 9 j 1813–1824 j December 12, 2017 1817
Figure 4. Different Strategies Generate HLCs with Different Gene Expression Patterns
(A) A small amount of fibrotic genes remained after hiHep direct transdifferentiation from fibroblasts. hiHep1 and hiHep2 were derived
from UCF1, hiHep3 and hiHep4 were derived from UCF2; iPSC-HLC1 and iPSC-HLC2 were derived from iPSC1, iPSC-HLC3 and iPSC-HLC4 were
derived from iPSC2. PHHs were fresh, or cultured for 1, 2, and 4 days.
(B and C) hiHeps did not express cholangiocyte (B) and intestine (C) lineage-specific genes. The combination of replicates is the same as in
(A).
(D and E) iPSC-HLCs remained definitive in endoderm (D) and liver progenitor (E) specific gene expression. The combination of replicates is
the same as (A).
See also Figures S4 and S5 and Table S2.Active Histone Modifications Are Detected during
hiHeps and iPSC-HLCs
The characteristics of a differentiated cell are stably main-
tained by histone modifications (Holmberg and Perlmann,
2012). In our experiments, we chose to analyze an active
pattern of histone modification, H3K27 acetylation
(H3K27ac) at active enhancer and promoter regions in1818 Stem Cell Reports j Vol. 9 j 1813–1824 j December 12, 2017both iPSC-HLCs and hiHeps. Furthermore, UCFs and fresh
human adult liver were used as negative and positive con-
trols (Bonn et al., 2012; Creyghton et al., 2010) (Table S2).
Thegenome-wide analysis ofH3K27acoccupancyexhibited
different patterns between the samples (Figures 5A and S6A)
and was divided into eight different clusters. Cluster A
included genes that have similar H3K27ac modifications
Figure 5. Characterization of H3K27ac Occupancy in Different Cell Types
(A) Distribution of the H3K27ac signals in the four samples. Genes that have H3K27ac in liver but not in UCF1 are shown.
(B) Gene Ontology analysis for the genes associated with H3K27ac peaks in different cluster groups in (A).
(C) Representative tracks of H3K27ac occupancy at housekeeping gene (ACTB), fibroblast-specific genes (THY1 and COL1A1), hepatic
specific genes (CDH1, TAT, UGT1A1, APOA2, APOE) across the four cell types. Red boxes mark the different H3K27ac peaks between hiHeps
and iPSC-HLCs.
See also Figure S6 and Table S2.in both HLCs and liver, including ALB, AAT, APOB, and
CDH1 (Figure5B). In clusterH,mostH3K27acmodifications
identified on fibrotic genes were erased in HLCs and liver(Figures S6A and S6B). Cluster D indicated hepatic genes
that were not fully modified by H3K27ac in HLCs (Fig-
ure 5B). Specifically, the enhancers and promoters nearStem Cell Reports j Vol. 9 j 1813–1824 j December 12, 2017 1819
Figure 6. In Vivo Characterization and Maturation of hiHeps and iPSC-HLCs after Repopulation
(A) Schematic outline of HLC transplantation into the livers of Fah//Rag2//Il2rg/ mice (FRG). Each mouse was transplanted
intrasplenically with 5 million HLCs.
(B) Human ALBUMIN levels in the sera of surviving mice from independent experiments were determined by ELISA. UCF-FRG included four
mice transplanted with two UCF1 and two UCF2; hiHep-FRG included six mice transplanted with two hiHep1, one hiHep2, two hiHep3, and
one hiHep4; iPSC-HLC-FRG included six mice transplanted with two iPSC-HLC1, one iPSC-HLC2, two iPSC-HLC3, and one iPSC-HLC4; PHH-
FRG included three mice transplanted with fresh PHHs.
(C) The repopulation of HLCs in FRG mouse livers was determined by immunostaining for FAH. Scale bar, 100 mm.
(D) Repopulation rates of HLCs in the liver of FRG mice were calculated. The combination of replicates is the same as in (B).
(E) FAH-positive hiHeps and iPSC-HLCs were collected by microdissection from serial liver sections. The mRNA levels of indicated genes
were measured in repopulated hiHeps and iPSC-HLCs, cultured hiHeps and iPSC-HLCs, PHH and liver by qPCR. Data are normalized to
cultured hiHeps. Cultured hiHeps included four replicates from independent experiments (hiHep1, hiHep2, hiHep3. and hiHep4).
(legend continued on next page)
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THY1 and COL1A1 were enriched with H3K27ac in UCFs
but erased inhiHeps and iPSC-HLCs (Figure5C). In contrast,
enhancer regions near CDH1, TAT, UGT1A1, APOA2, and
APOE were enriched in H3K27ac in hiHep and iPSC-HLCs
when compared with UCFs (Figure 5C). This finding not
only demonstrated that both hiHeps and iPSC-HLCs gained
stable epigenetic modifications but also proved that hiHeps
and iPSC-HLCshadactivehepatic gene expression. In accor-
dance with previous analysis, there were differences be-
tween iPSC-HLCs and hiHeps with differential acetylation
observed at enhancers near TAT and UGT1A1 in hiHep,
whereas in iPSC-HLCs, enhancers near APOA2 and APOE
were more active (Figure 5C).
Improvements in Hepatocyte Phenotype Were
Detected Following hiHep and iPSC-HLC Transplant
In Vivo
The analysis of histone active markers partially explained
the similarities and differences between iPSC-HLCs and
hiHeps. Given the plasticity of histone modifications, it is
possible to further improve the hepatic features of iPSC-
HLCs andhiHeps if a niche is supplied.We decided to trans-
plant these cells into the liver, whichmay represent the best
microenvironment for hepatocytes. hiHeps and iPSC-HLCs
were transplanted into Fah/Rag2/Il2rg/ (FRG) mice
via splenic injection. FRG mice were kept alive with a sup-
ply of 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3-cyclohexa-
nedione (NTBC). After NTBCwithdrawal, FRGmice usually
die of metabolic liver disease within 4–6 weeks (Azuma
et al., 2007). We transplanted five million hiHeps and
iPSC-HLCs into FRG mice and analyzed liver repopulation
after transplantation (Figure 6A). FRG mice transplanted
with UCF and PHH were used as controls. After 2 months,
human ALBUMIN levels were at comparable levels in the
sera of FRG mice transplanted with hiHeps (153 ±
42 ng/mL) and iPSC-HLCs (114 ± 50 ng/mL) but were low
compared with PHHs (0.91 ± 0.16 mg/mL) (Figure 6B).
Immunohistochemical staining for human FAH showed
that repopulation efficiencies were similar for hiHeps and
iPSC-HLCs with contributions ranging from 0.3% to 4.2%
(1.95% ± 1.49%) and 0.2%–4.6% (1.75% ± 1.65%) respec-
tively, which were much lower than that of PHHs (Figures
6C, 6D, and S6C). Even though HLCs could repopulate
into the livers of FRG mice, they did not secret human
ALBUMIN as efficiently as PHHs, which suggested that
they were not mature enough for hepatic function.
To evaluate whether hiHeps and iPSC-HLCs were
further matured following exposure to the in vivo niche,Repopulated hiHeps included two independent replicates from hiHep
iPSC-HLCs included four replicates from independent experiments (iPS
HLCs included two independent replicates from iPSC-HLC1-FRG and tw
See also Figure S6.we micro-dissected repopulated nodules from liver
sections. Expression of hepatocyte genes was determined
in hiHeps and iPSC-HLCs by qPCR using human-specific
primers. Compared with cultured hiHeps and iPSC-
HLCs, the expression levels of several genes were signifi-
cantly increased after repopulation, including CYP3A4
and F11 (Figure 6E). In addition, we characterized the
mRNA levels of lipid metabolism and phase II meta-
bolism-related genes. Markedly, the expression differ-
ences discovered in cultured HLCs were normalized in
repopulated hiHeps and iPSC-HLCs, suggesting that the
in vivo microenvironment improved hepatic gene expres-
sion. Taken together, our results demonstrate that
iPSC-HLCs and hiHeps have the potential to be further
matured if the niche they are maintained in is supportive.DISCUSSION
To rule out donor variability, iPSC-HLCs and hiHeps were
generated from the same parental cells (Kajiwara et al.,
2012; Ma et al., 2014). In general, both types of HLCs
were comparable, with gene expression patterns similar
to PHHs, but with obvious differences. In vitro functional
analysis demonstrated that iPSC-HLCs and hiHeps were
comparable, with HLCs demonstrating glycogen storage,
ALBUMIN, alpha-1-antitrypsin, and biliary excretion.
Notably, when iPSC-HLCs and hiHeps were transplanted
intomouse livers, they repopulated the liver at comparable
levels and demonstrated comparable gene expression.
Taken together, these findings demonstrate that both
directed differentiation and transdifferentiation success-
fully instruct hepatic differentiation, cell engraftment
in vivo, and similar maturation.
While similarities were observed, differences between
hiHeps and iPSC-HLCs existed in vitro. Comparison of
global gene expression profiles highlighted that iPSC-
HLCs express several endoderm progenitor- and hepato-
blast-related marker genes as previously reported (Carpent-
ier et al., 2014; Godoy et al., 2015). The induction of
iPSC-HLCs was achieved using an affordable and facile
three-staged protocol mimicking certain aspects of human
hepatocyte development. The in vitro differentiation dura-
tion is significantly shorter than human development in
utero, therefore residual molecular traces left during iPSC-
HLC formation could have restricted cell maturation. In
addition, the cell niche, and in particular the extracellular
matrix, has been shown to be an important driver of HLC1-FRG and two independent replicates from hiHep3-FRG. Cultured
C-HLC1, iPSC-HLC2, iPSC-HLC3, and iPSC-HLC4). Repopulated iPSC-
o independent replicates from iPSC-HLC3-FRG.
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differentiation, and therefore these areas require further
investigation (Cameron et al., 2015).
It was previously reported that mouse iHep cells induced
by Foxa3 and Hnf4a express the colon epithelium-specific
marker gene Cdx2, suggesting that transdifferentiation
might detour cells into unwanted lineages if not properly
controlled (Morris et al., 2014). However, we did not
observe such colon-specific gene expression in our hiHeps.
In our studies, the functional assays further validated those
findings from gene expression analyses. These data suggest
that both iPSC-HLCs and hiHeps have advantages in
modeling different aspects of human liver biology ‘‘in a
dish.’’ Specifically, iPSC-HLCs may be a better model to
study fatty liver diseases, whereas hiHeps could be the
choice for in vitro phase II drug metabolism. HLCs were
compared with PHHs with and without culture in this
study. While cultured hepatocytes do not completely
reflect the nature of primary hepatocytes in vivo, they
might be sufficient for these types of comparisons if one
wishes to normalize the effect caused by in vitro culture.
Although functional differences were observed between
the HLCs, cell repopulation of immune-deficient Fah/
mice using iPSC-HLCs or hiHeps was comparable. Impor-
tantly, this translated into improvements in liver physi-
ology and murine survival rates providing promise for the
clinic in the future. Importantly, iPSC-HLC or hiHep plas-
ticity was observed in vivo, indicating that HLCs responded
to their environment, leading to improvements in cell
phenotype. While these studies demonstrate significant
advances, it should be noted that iPSC-HLCs and hiHeps
were still not as efficient at engrafting as PHHs in FRG
mice. This highlights the need to improve hepatic matura-
tion and/or liver preconditioning, prior to cell transplanta-
tion in the future (Fisher and Strom, 2006; Grompe and
Strom, 2013; Yang et al., 2017).
Our findings not only suggest potential applications for
iPSC-HLCs and hiHeps but also provide insight about the
process of differentiation and transdifferentiation. The
identification of differentiated cells is mainly determined
by regulation of tissue-specific transcription factors and
epigenetic modifications (Holmberg and Perlmann,
2012). In support of this, we demonstrate that HLCs gener-
ated from both transdifferentiation and directed differenti-
ation had stable epigenetic modifications, which had an
impact on their function in vitro. These studies also confirm
that both hiHeps and iPSC-HLCs are partially differentiated
in 2D culture in vitro. Going forward, it will be necessary to
identify new potential combinations of transcription and
growth factors to improve transdifferentiation and directed
differentiation. In addition, new strategies such as 3D
differentiation (Rashidi et al., 2016; Takebe et al., 2013)
and alternative substrates may improve the maturation of
both types of HLCs (Cameron et al., 2015; Lim et al., 2016).1822 Stem Cell Reports j Vol. 9 j 1813–1824 j December 12, 2017Despite the divergences between HLCs and PHHs, HLCs
have been alreadyproveduseful for in vitrodiseasemodeling
and cell-based therapies (Forbes et al., 2015; Shi et al., 2016).
Going forward, it is critical to unveil the differences that
exist between HLCs and PHHs to improve cell phenotype
further. This will lead to improved models for the lab and
cells for the clinic in the future (Nicolas et al., 2017).EXPERIMENTAL PROCEDURES
Cell Culture and Generation of Hepatocyte-like Cells
UCFs were cultured in human fibroblast medium. hiHeps were
generated from immortalized UCFs with transduction of FOXA3,
HNF1A, and HNF4A, and cultured in hepatocyte-maintaining
medium as previously reported (Huang et al., 2014). Human iPSCs
were generated from UCFs by transduction of retrovirus (OCT4,
SOX2, KLF4, and C-MYC). iPSC-HLCs were generated from iPSCs
through a three-step method as previously reported (Szkolnicka
et al., 2014).
Primary Hepatocyte Culture
PHHs from three individuals were purchased from Celsis In Vitro
Technologies. PHHs were pooled together in the same number
and plated at a density of 1.25 3 105/cm2. For the testosterone
clearance assay, we used freshly thawed PHHs. For the other assays,
the days of culture of PHHs are indicated. Institutional ethical
committees approved the collection and use of human samples.
Mice
FRGmice were maintained with NTBC water at a concentration of
16mg/L. NTBCwater was withdrawn 1 week before the transplan-
tation of HLCs. hiHeps and iPSC-HLCs (53 106 cells/animal) were
injected into the spleens of the mice. All mouse experiments were
approved by the Institutional Animal Care and Use Committee of
the Institute of Biochemistry and Cell Biology and performed in
accordance with institutional guidelines.
RNA-Seq Analysis
Total RNA was isolated from UCFs, hiHeps, iPSC-HLCs, and PHHs
by Trizol. RNA-seq librarieswere preparedwith the Illumina TruSeq
RNA Sample Preparation Kit. The fragmented and randomly
primed 100 bp paired-end libraries were sequenced on an Illumina
HiSeq 2000 sequencing system.
ChIP-Seq Analysis
Chromatin immunoprecipitation (ChIP) was performed using
antibodies for acetylation of histone H3 lysine 27 acetylation
(H3K27ac, Abcam Ab4729). DNA libraries of matched input and
ChIP sampleswere prepared using the Illumina Truseq kit, indexed
formultiplexed runs of four libraries per lane, and sequenced on an
Illumina HiSeq2000 instrument.
Statistical Analysis
Data were subjected to Student’s t test. p < 0.05 was considered
statistically significant. Data are presented as means ± SD.
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